Immutep Ltd Stock Australian S.E.
Equities
AU000000PRR9
Biotechnology & Medical Research
Sales 2024 * | 3.19M 2.08M | Sales 2025 * | 19.78M 12.92M | Capitalization | 499M 326M |
---|---|---|---|---|---|
Net income 2024 * | -45M -29.39M | Net income 2025 * | -40M -26.13M | EV / Sales 2024 * | 132 x |
Net cash position 2024 * | 78.66M 51.38M | Net cash position 2025 * | 50.71M 33.12M | EV / Sales 2025 * | 22.7 x |
P/E ratio 2024 * |
-10.8
x | P/E ratio 2025 * |
-12.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |